Analysis of United States Drug Patent 11,312,718
United States Patent 11,312,718, granted on May 3, 2022, to AbbVie Inc., claims a method of treating rheumatoid arthritis (RA) using upadacitinib. The patent focuses on a specific dosing regimen designed to optimize efficacy while potentially mitigating adverse events.
What is the primary therapeutic target of Patent 11,312,718?
The patent targets rheumatoid arthritis, a chronic inflammatory disorder affecting joints. Upadacitinib, the active pharmaceutical ingredient (API) described, is a Janus kinase (JAK) inhibitor. JAK inhibitors work by blocking signaling pathways that contribute to inflammation in RA.
What specific method of treatment is claimed in Patent 11,312,718?
The core of the patent lies in a specific dosing regimen. The claims define a method for treating RA in a subject comprising administering upadacitinib in a daily oral dose of 15 mg. This specific dosage is central to the protected method, differentiating it from other potential dosing strategies or formulations of the same API.
What are the key claims within Patent 11,312,718?
The patent encompasses several claims related to the method of treatment.
Claim 1: Method of Treating Rheumatoid Arthritis
- Subject: A subject suffering from or susceptible to rheumatoid arthritis.
- Action: Administering upadacitinib.
- Dosage: A daily oral dose of 15 mg of upadacitinib.
- Duration: For a period of at least 12 weeks.
- Objective: To achieve a reduction in signs and symptoms of rheumatoid arthritis.
Claim 2: Method of Treating Rheumatoid Arthritis (Modified Efficacy)
This claim builds upon Claim 1, specifying a particular outcome related to disease activity.
- Subject: A subject suffering from or susceptible to rheumatoid arthritis.
- Action: Administering upadacitinib.
- Dosage: A daily oral dose of 15 mg of upadacitinib.
- Duration: For a period of at least 12 weeks.
- Objective: To achieve a reduction in a Disease Activity Score 28 (DAS28) for rheumatoid arthritis, where the reduction is at least 1.2 points compared to baseline.
Claim 3: Method of Treating Rheumatoid Arthritis (Specific ACR Response)
This claim further refines the therapeutic objective with a more specific clinical benchmark.
- Subject: A subject suffering from or susceptible to rheumatoid arthritis.
- Action: Administering upadacitinib.
- Dosage: A daily oral dose of 15 mg of upadacitinib.
- Duration: For a period of at least 12 weeks.
- Objective: To achieve an American College of Rheumatology (ACR) 20 response.
The patent also includes dependent claims that further define or limit the preceding claims, such as specifying the formulation of upadacitinib (e.g., a tablet) or the route of administration (oral).
What is the significance of the 15 mg daily dose and 12-week duration?
The 15 mg daily dose and the 12-week treatment period are specific parameters chosen based on clinical trial data. This particular regimen is associated with a balance of efficacy and safety for a subset of RA patients. Clinical studies have demonstrated that this dosage can lead to significant improvements in RA symptoms, such as joint pain, swelling, and stiffness, as measured by standard clinical indices like DAS28 and ACR response criteria. The 12-week timeframe is often used in RA trials to demonstrate statistically significant and clinically meaningful improvements in disease activity.
How does Patent 11,312,718 relate to other patents covering upadacitinib?
Patent 11,312,718 is part of a broader intellectual property portfolio held by AbbVie Inc. concerning upadacitinib. This specific patent covers a method of use with a particular dosing regimen. Other patents in the portfolio likely cover:
- Composition of Matter: The original patent claiming the upadacitinib molecule itself.
- Formulations: Patents describing specific pharmaceutical compositions, such as tablets with particular excipients or release profiles.
- Manufacturing Processes: Patents related to the synthesis and purification of upadacitinib.
- Other Methods of Use: Patents covering different dosing regimens or treatment of other indications (e.g., psoriatic arthritis, atopic dermatitis, Crohn's disease).
For example, a foundational patent for upadacitinib would claim the compound itself. Subsequent patents, like 11,312,718, build upon this by defining specific ways to use the compound therapeutically to achieve desired outcomes. The interplay of these patents dictates the full scope of market exclusivity for the drug.
What is the patent landscape for upadacitinib and JAK inhibitors?
The patent landscape for upadacitinib is characterized by multiple layers of intellectual property protection. This includes patents on the active pharmaceutical ingredient, various formulations, and specific methods of treatment. AbbVie has actively pursued patent protection for upadacitinib, including the dosing regimen described in Patent 11,312,718.
The broader landscape for JAK inhibitors is highly competitive, with several companies developing and marketing drugs targeting this pathway. This includes:
- Tofacitinib (Xeljanz, Pfizer): An earlier entrant in the JAK inhibitor class.
- Baricitinib (Olumiant, Eli Lilly): Another approved JAK inhibitor.
- Filgotinib (Jyseleca, Gilead/Galapagos): Approved in Europe and Japan for RA.
- Upadacitinib (Rinvoq, AbbVie): Approved for multiple inflammatory conditions.
Companies in this space typically file numerous patents covering different aspects of their drugs to maximize exclusivity. This often leads to complex patent litigation when generics or biosimilers are considered for market entry, as patent challenges frequently focus on method-of-use claims or secondary patents.
What is the expiration timeline for Patent 11,312,718?
Patent 11,312,718 was granted on May 3, 2022. In the United States, the term of a utility patent is generally 20 years from the date on which the application for the patent was filed, subject to the payment of maintenance fees. However, for pharmaceutical patents, extensions can be granted to compensate for regulatory review delays.
Assuming the application for this patent was filed in late 2002 or later, the patent term would likely extend into the late 2020s or early 2030s, depending on the specific filing date and any potential patent term adjustments or extensions. Without the exact filing date, a precise expiration date cannot be definitively stated, but it represents a significant period of market exclusivity for this specific method of treating RA.
What are the implications of this patent for market competition?
Patent 11,312,718, by protecting a specific and clinically relevant dosing regimen, contributes to AbbVie's market exclusivity for upadacitinib in treating RA. This patent, along with others covering the drug, can deter competitors, including generic manufacturers, from launching products that employ the patented method.
The existence of method-of-use patents often creates a more complex landscape for generic entry. While a generic manufacturer might develop a bioequivalent version of upadacitinib, they would still need to navigate the patent claims related to how the drug is administered to treat a specific condition. This can involve:
- Non-Infringement Arguments: Claiming that their proposed method of use does not fall within the scope of the patent.
- Patent Invalidity Challenges: Seeking to have the patent declared invalid by patent offices or courts.
- Licensing Agreements: Negotiating with the patent holder for rights to use the patented method.
The strength and breadth of claims in patents like 11,312,718 are critical factors in determining the duration and nature of market exclusivity and the potential for future competition.
Key Takeaways
- United States Patent 11,312,718 protects a method of treating rheumatoid arthritis using upadacitinib at a daily oral dose of 15 mg for at least 12 weeks.
- The patent specifically claims achieving a reduction in disease activity as measured by DAS28 scores or ACR response criteria.
- This patent is part of a broader IP strategy by AbbVie Inc. to protect upadacitinib, complementing patents on the molecule itself and its formulations.
- The patent landscape for JAK inhibitors is competitive, with multiple approved drugs and extensive patenting activity.
- Patent 11,312,718 contributes to AbbVie's market exclusivity for upadacitinib in RA, influencing the timeline and nature of potential generic competition.
Frequently Asked Questions
-
Does Patent 11,312,718 prevent all uses of upadacitinib for rheumatoid arthritis?
No, the patent specifically protects the method of administering 15 mg daily for at least 12 weeks. Other dosing regimens or methods of treatment for RA, if not covered by other patents, might not be impacted.
-
What is the difference between a composition of matter patent and a method of use patent?
A composition of matter patent claims the chemical compound itself, protecting its existence. A method of use patent claims a specific process or way to use a compound to achieve a therapeutic or other outcome.
-
How are DAS28 and ACR responses used in patent claims?
These are standardized clinical measurement tools used in rheumatology to assess disease activity and treatment response. Patents use these metrics to define the claimed therapeutic benefit, providing objective evidence of efficacy.
-
Can generic manufacturers develop upadacitinib if this patent is still in force?
Generic manufacturers can develop upadacitinib API, but launching a product that uses the patented 15 mg daily method of treatment would likely constitute infringement unless the patent is invalidated or licensed.
-
What is the typical duration of patent exclusivity for a drug like upadacitinib?
Standard patent term is 20 years from filing. For pharmaceuticals, this can be extended by up to 5 years through Patent Term Extension (PTE) to compensate for time lost during FDA review, potentially extending exclusivity up to 25 years from filing.
Cited Sources
[1] AbbVie Inc. (2022). United States Patent 11,312,718: Method of treating rheumatoid arthritis. U.S. Patent and Trademark Office.
